Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study
Juan José Lahuerta(Research Institute Hospital 12 de Octubre), Laura Rosiñol(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Felipe de Arriba(Hospital General Universitario Morales Meseguer), Lourdes Escoda(Hospital Universitari Joan XXIII de Tarragona), Jesús F. San Miguel(Clinica Universidad de Navarra), Joan Bladé(Hospital Clínic de Barcelona), Javier de la Rubia(Universitat de València), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Adrían Alegre(Hospital Universitario de La Princesa), Concepción Rivas-González(Centro de Investigación del Cáncer), Albert Oriol(Institut Català d'Oncologia), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Joan Besalduch(Hospital Universitario Son Dureta), José García‐Laraña, Javier García‐Frade(Centro de Investigación del Cáncer), Miguel Teodoro Hernández‐Garcia(Centro de Investigación del Cáncer), J Díaz-Mediavilla(Hospital de Sant Pau), M.V. Mateos(Hospital de Sant Pau), Carlos Grande(Research Institute Hospital 12 de Octubre), D. Carrera(Hospital de Sant Pau)
Cited by 113
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k